3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
3
Myelodysplastic Syndromes
2
Pancreatic Neoplasms
1
Mesothelioma, Malignant
1
Melanoma
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
cilgavimab and tixagevimab drug combination
2
Standard of Care
2
Specimen Handling
2
Practice Guidelines as Topic
2
CVnCoV COVID-19 vaccine
2
COH04S1 COVID-19 vaccine
2
BNT162 Vaccine
2
sotrovimab
1
ogalvibart
1
crexavibart
1
bemcentinib
1
Therapeutics
1
Surveys and Questionnaires
1
Hydroxychloroquine
1
HuMax-IL8
1
Data Collection
1
COVID-19 Vaccines
1
Blood Specimen Collection
1
Azithromycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
COVID-19
×
bemcentinib
×
Other hematologic neoplasm
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts